The Glivec International Patient Assistance Program (GIPAP) is a global program that was established by Novartis Pharma AG in 2001 and implemented in partnership with The Max Foundation and Axios International, to provide imatinib (Glivec) at no cost to eligible patients with CML or gastrointestinal stromal tumor (GIST)
Full Answer
What is Glivec in Axios?
As the extent of the cancer burden in developing countries was coming to the forefront, Novartis enlisted the support of Axios to help determine what they could do to address this growing epidemic. The result was the Glivec International Patient Assistance Program (GIPAP) – established by Novartis in 2002 in collaboration with Axios International and The Max Foundation. Through GIPAP, Glivec (imatinib) was donated free-of-charge to patients living with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or with c-Kit (CD117) positive unresectable (inoperable) and/or metastatic malignant gastrointestinal stromal tumors (GISTs).
When was GIPAP established?
Established in 2002, GIPAP was one of the first programs to tackle the growing cancer epidemic in developing countries on a global scale.
What is GIPAP model?
GIPAP represents an innovative drug donation model that has set the standard for access programs for other targeted or innovative therapies. The purpose of this article is to describe the structure of GIPAP, as well as important lessons that have contributed to the success of the program.
When was imatinib approved?
It was subsequently approved for the treatment of GI stromal tumor (GIST) in 2002. 5.
What was the first targeted therapy approved for the treatment of cancer?
DISCUSSION REFERENCES. Imatinib was the first targeted therapy approved for the treatment of cancer. With its approval, it was immediately clear to Novartis that this breakthrough therapy would require an innovative approach to worldwide access, with special consideration of low- and middle-income countries.
Does Novartis pay for imatinib?
Under NOA, Novartis shares the cost of imatinib either with government health care systems, charities, and other payers or directly with patients without health care coverage who are unable to pay for the full cost of their medication but can pay it in part under a copay model.